BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marra AR, Perencevich EN, Nelson RE, Samore M, Khader K, Chiang HY, Chorazy ML, Herwaldt LA, Diekema DJ, Kuxhausen MF, Blevins A, Ward MA, McDanel JS, Nair R, Balkenende E, Schweizer ML. Incidence and Outcomes Associated With Clostridium difficile Infections: A Systematic Review and Meta-analysis. JAMA Netw Open 2020;3:e1917597. [PMID: 31913488 DOI: 10.1001/jamanetworkopen.2019.17597] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 11.5] [Reference Citation Analysis]
Number Citing Articles
1 Hurley JC. Oral Vancomycin Prophylaxis for Clostridioides difficile Infection: Cause or Effect? Clin Infect Dis 2021;73:e2850-1. [PMID: 32948875 DOI: 10.1093/cid/ciaa1424] [Reference Citation Analysis]
2 Khanna S, Pardi DS, Jones C, Shannon WD, Gonzalez C, Blount K. RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients' Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections. Clin Infect Dis 2021;73:e1613-20. [PMID: 32966574 DOI: 10.1093/cid/ciaa1430] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
3 Al Muqati H, Al Turaiki A, Al Dhahri F, Al Enazi H, Althemery A. Superinfection rate among the patients treated with carbapenem versus piperacillin/tazobactam: Retrospective observational study. J Infect Public Health 2021;14:306-10. [PMID: 33618274 DOI: 10.1016/j.jiph.2020.11.015] [Reference Citation Analysis]
4 Kabała M, Gofron Z, Aptekorz M, Sacha K, Harmanus C, Kuijper E, Martirosian G. Clostridioides difficile Ribotype 027 (RT027) Outbreak Investigation Due to the Emergence of Rifampicin Resistance Using Multilocus Variable-Number Tandem Repeat Analysis (MLVA). Infect Drug Resist 2021;14:3247-54. [PMID: 34429622 DOI: 10.2147/IDR.S324745] [Reference Citation Analysis]
5 Heindl SE, Tsouklidis N. Appendectomy as a Potential Predisposing Factor for the Development of Recurrent and Fulminant Clostridium Difficile. Cureus 2020;12:e10091. [PMID: 32874818 DOI: 10.7759/cureus.10091] [Reference Citation Analysis]
6 Labajová N, Baranova N, Jurásek M, Vácha R, Loose M, Barák I. Cardiolipin-Containing Lipid Membranes Attract the Bacterial Cell Division Protein DivIVA. Int J Mol Sci 2021;22:8350. [PMID: 34361115 DOI: 10.3390/ijms22158350] [Reference Citation Analysis]
7 Bérot V, Choinier P, Drieux-Rouzet L, Trystram D, Junot H, Robert J, Bleibtreu A. Impact of stewardship strategy on antibiotic use in Clostridoidesdifficile infection. Infect Dis Now 2021;51:499-501. [PMID: 34366087 DOI: 10.1016/j.idnow.2020.10.009] [Reference Citation Analysis]
8 Sierocka A, Kiersnowska Z, Lemiech-Mirowska E, Marczak M. Costs Associated with the Treatment of Clostridioides Difficile Infections. Int J Environ Res Public Health 2021;18:7647. [PMID: 34300098 DOI: 10.3390/ijerph18147647] [Reference Citation Analysis]
9 Sheffield ME, Jones BM, Terrell B, Wagner JL, Bland CM. Influence of Probiotics on the Development of Clostridioides difficile Infection in Patients Receiving Fluoroquinolones. Pharmacy (Basel) 2021;9:141. [PMID: 34449745 DOI: 10.3390/pharmacy9030141] [Reference Citation Analysis]
10 Morales-Marroquin E, Xie L, Uppuluri M, Almandoz JP, Cruz-Muñoz N, Messiah SE. Immunosuppression and Clostridioides (Clostridium) difficile Infection Risk in Metabolic and Bariatric Surgery Patients. J Am Coll Surg 2021;233:223-31. [PMID: 34015452 DOI: 10.1016/j.jamcollsurg.2021.04.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Voicu MN, Popescu F, Florescu DN, Rogoveanu I, Turcu-Stiolica A, Gheonea DI, Iovanescu VF, Iordache S, Cazacu SM, Ungureanu BS. Clostridioides difficile Infection among Cirrhotic Patients with Variceal Bleeding. Antibiotics (Basel) 2021;10:731. [PMID: 34204307 DOI: 10.3390/antibiotics10060731] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Phanchana M, Harnvoravongchai P, Wongkuna S, Phetruen T, Phothichaisri W, Panturat S, Pipatthana M, Charoensutthivarakul S, Chankhamhaengdecha S, Janvilisri T. Frontiers in antibiotic alternatives for Clostridioides difficile infection. World J Gastroenterol 2021; 27(42): 7210-7232 [PMID: 34876784 DOI: 10.3748/wjg.v27.i42.7210] [Reference Citation Analysis]
13 Gerding DN. Incidence and Outcome of Clostridium difficile Infection-Beware of Strain Type and Diagnostic Tests. JAMA Netw Open 2020;3:e1918599. [PMID: 31913485 DOI: 10.1001/jamanetworkopen.2019.18599] [Reference Citation Analysis]
14 Fettucciari K, Fruganti A, Marchegiani A, Brancorsini S, Marconi P, Bassotti G. Proinflammatory Cytokines: Possible Accomplices for the Systemic Effects of Clostridioides difficile Toxin B. J Inflamm Res 2021;14:57-62. [PMID: 33469335 DOI: 10.2147/JIR.S287096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Sahu KK, Mishra AK, Jindal V, Siddiqui AD, George SV. To study the contributing factors and outcomes of Clostridioides difficile infection in patients with solid tumors. Heliyon 2021;7:e08450. [PMID: 34926847 DOI: 10.1016/j.heliyon.2021.e08450] [Reference Citation Analysis]
16 Wendelboe AM, Kim SE, Kinney S, Cuellar AE, Salinas L, Chou AF. Cost-Benefit Analysis of Allowing Additional Time in Cleaning Hospital Contact Precautions Rooms. Hosp Top 2021;99:130-9. [PMID: 33459211 DOI: 10.1080/00185868.2021.1873083] [Reference Citation Analysis]
17 Poylin V, Hawkins AT, Bhama AR, Boutros M, Lightner AL, Khanna S, Paquette IM, Feingold DL; Prepared by the Clinical Practice Guidelines Committee of The American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Clostridioides difficile Infection. Dis Colon Rectum 2021;64:650-68. [PMID: 33769319 DOI: 10.1097/DCR.0000000000002047] [Reference Citation Analysis]
18 Negrut N, Nistor-cseppento DC, Khan SA, Pantis C, Maghiar TA, Maghiar O, Aleya S, Rus M, Tit DM, Aleya L, Rahdar A, Bungau S. Clostridium difficile Infection Epidemiology over a Period of 8 Years—A Single Centre Study. Sustainability 2020;12:4439. [DOI: 10.3390/su12114439] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
19 Karyal C, Hughes J, Kelly ML, Luckett JC, Kaye PV, Cockayne A, Minton NP, Griffin R. Colonisation Factor CD0873, an Attractive Oral Vaccine Candidate against Clostridioides difficile. Microorganisms 2021;9:306. [PMID: 33540694 DOI: 10.3390/microorganisms9020306] [Reference Citation Analysis]
20 Ponce-Alonso M, García-Fernández S, Del Campo R. Challenges of landscaping and modulation strategies in human intestinal microbiota. Enferm Infecc Microbiol Clin (Engl Ed) 2021;39:165-7. [PMID: 33627246 DOI: 10.1016/j.eimc.2021.02.001] [Reference Citation Analysis]
21 Brodzicki A, Jaworek-Korjakowska J, Kleczek P, Garland M, Bogyo M. Pre-Trained Deep Convolutional Neural Network for Clostridioides Difficile Bacteria Cytotoxicity Classification Based on Fluorescence Images. Sensors (Basel) 2020;20:E6713. [PMID: 33255305 DOI: 10.3390/s20236713] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
22 Cojocariu C, Girleanu I, Trifan A, Olteanu A, Muzica CM, Huiban L, Chiriac S, Singeap AM, Cuciureanu T, Sfarti C, Stanciu C. Did the severe acute respiratory syndrome-coronavirus 2 pandemic cause an endemic Clostridium difficile infection? World J Clin Cases 2021; 9(33): 10180-10188 [PMID: 34904088 DOI: 10.12998/wjcc.v9.i33.10180] [Reference Citation Analysis]
23 O'Donnell JN, Novak GM, Bratek BR, Singh G, Duru OO, Mitchell CL, Roddy KM, Bidell MR. Effect of oral vancomycin dose on outcomes in patients with Clostridioides difficile infection. Int J Antimicrob Agents 2021;57:106311. [PMID: 33621602 DOI: 10.1016/j.ijantimicag.2021.106311] [Reference Citation Analysis]